New drug combo available for BRAF-Positive melanoma patients

NCT ID NCT04489433

NO_LONGER_AVAILABLE Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This program provides access to the drugs trametinib and dabrafenib for adults with BRAF mutation-positive metastatic melanoma that cannot be surgically removed. Participants take dabrafenib twice daily and trametinib once daily. The goal is to offer treatment to eligible patients who have no other options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dabrafenib and trametinib

What this could lead to

If successful, this could offer a treatment option for people with advanced melanoma who have a specific BRAF mutation.

What could go wrong

This is an access program, not a formal trial, so results are not systematically collected. The drugs may cause side effects like fever, rash, or heart problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA